Review article: the economic impact of the irritable bowel syndrome
Top Cited Papers
- 9 September 2014
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 40 (9), 1023-1034
- https://doi.org/10.1111/apt.12938
Abstract
Background: Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal system affecting a large number of people worldwide. Whilst it has no attributable mortality, it has substantial impact on patients' quality of life (QoL) and is associated with considerable healthcare resource use. \ud \ud Aim: To review the economic impact of IBS, firstly on the individual, secondly on healthcare systems internationally and thirdly to society. \ud \ud Methods: Appropriate databases were searched for relevant papers using the terms: Irritable Bowel Syndrome; IBS; irritable colon; functional bowel/colonic disease; economics; health care/service costs; health expenditure/resources; health care/service utilisation; productivity. \ud \ud Results: Irritable bowel syndrome impacts most substantially on patients' work and social life. Reduction in QoL is such that on average patients would sacrifice between 10 and 15 years of their remaining life expectancy for an immediate cure. Between 15% and 43% of patients pay for remedies. No studies quantify loss of earnings related to IBS. Direct care costs are substantial; 48% of patients incur some costs in any year with annual international estimates per patient of: USA $742–$7547, UK £90–£316, France €567–€862, Canada $259, Germany €791, Norway NOK 2098 (€262) and Iran $92. Minimising extensive diagnostic investigations could generate savings and has been shown as not detrimental to patients. Cost to industry internationally through absenteeism and presenteeism related to IBS is estimated between £400 and £900 per patient annually. \ud \ud Conclusions: costs to patients, healthcare systems and society. Considerable benefit could be obtained from effective interventionsKeywords
Funding Information
- Medical Research Council (G1002360)
This publication has 57 references indexed in Scilit:
- Impact of symptoms on quality of life before and after diagnosis of coeliac disease: results from a UK population surveyBMC Health Services Research, 2010
- The Yield of Colonoscopy in Patients With Non-Constipated Irritable Bowel Syndrome: Results From a Prospective, Controlled US TrialThe American Journal of Gastroenterology, 2010
- Is Irritable Bowel Syndrome a Diagnosis of Exclusion? A Survey of Primary Care Providers, Gastroenterologists, and IBS ExpertsThe American Journal of Gastroenterology, 2010
- How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practiceBMC Gastroenterology, 2010
- Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in GermanyInflammatory Bowel Diseases, 2010
- Guidelines on the irritable bowel syndrome: mechanisms and practical managementGut, 2007
- Prevalence, Sociodemography, and QualitLife of Older Versus Younger Patients with Irritable Bowel Syndrome: A Population-Based StudyDigestive Diseases and Sciences, 2006
- Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?Gastrointestinal Endoscopy, 2005
- Utilization of colonoscopy in the United States: results from a national consortiumGastrointestinal Endoscopy, 2005
- Theoretical issues in cost-effectiveness analysisJournal of Health Economics, 1997